When was Apellis Pharmaceuticals founded?

Apellis Pharmaceuticals was founded in 2008 and raised its 1st funding round within a year of its incorporation.

Where is Apellis Pharmaceuticals located?

Apellis Pharmaceuticals is headquartered in Crestwood, United States.

Who is the current CEO of Apellis Pharmaceuticals?

Cedric Francois of Apellis Pharmaceuticals. They have also founded 1 company.

How many employees does Apellis Pharmaceuticals have?

As of Mar 31, 2026, the latest employee count at Apellis Pharmaceuticals is 816.

Is Apellis Pharmaceuticals a funded company?

Apellis Pharmaceuticals is a funded company, having raised a total of $213M across 13 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Jul 01, 2008.

When was the latest funding round of Apellis Pharmaceuticals?

Apellis Pharmaceuticals' latest funding was a $***** Post IPO round on May 07, 2020, with participation from 0 investor.

What is the annual revenue of Apellis Pharmaceuticals?

Annual revenue of Apellis Pharmaceuticals is $1B as on Dec 31, 2025.

Where does Apellis Pharmaceuticals rank among its competitors?

Apellis Pharmaceuticals ranks 36th amongst 3158 active competitors, of which 1069 are funded. It stands 7th in terms of total funding among its competitors. The most recent competitor to raise funding was BridgeBio, which secured $200M in Apr, 2024.

Who are the top competitors of Apellis Pharmaceuticals?

Apellis Pharmaceuticals' top competitors include Jazz Pharmaceuticals, Alnylam and BridgeBio. Among them, BridgeBio secured the most recent funding round in April, 2024.

Apellis Pharmaceuticals - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

Developer of therapeutics for the treatment of rare diseases. The company is developing transformative therapies for people living with a broad range of debilitating diseases by controlling complement, part of the body’s immune system. The company develops programs across ophthalmology, nephrology, hematology, and neurology.

Website: apellis.com
Social

Key Metrics

Founded Year

2008

Location

Crestwood, United States

Stage

Acquired

Total Funding

$213M in 13 rounds

Latest Funding Round

Post IPO, May 07, 2020, $*****

Investors

Morningside & 22 more

Ranked

36^th among 3158 active competitors

Annual Revenue

$1B as on Dec 31, 2025

Employee Count

816 as on Mar 31, 2026

Similar Companies

Alnylam & 1031 more

Exit Details

Acquired by Biogen (Mar 31, 2026)

View Apellis Pharmaceuticals' full profile

Apellis Pharmaceuticals is associated with 6 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Apellis Pharmaceuticals, Inc. CIN: 214632499 , United States, Active	Jul 17, 2023	-	-	-
APELLIS PHARMACEUTICALS, INC. CIN: 1492422 , United States, Active	Sep 24, 2009	$1B (As on Dec 31, 2025)	-	-
Apellis Pharmaceuticals, Inc. CIN: 20181328397 , United States, Active	Apr 23, 2018	$1 - $1M (As on Jun 09, 2015)	-	-
APELLIS PHARMACEUTICALS CIN: 271537290 , United States, Active		-	615 (As on Dec 31, 2024)	-
Apellis Pharmaceuticals, Inc. CIN: 32069752759 , United States, Active	Feb 13, 2019	-	-	-
Apellis Estonia OÜ CIN: 14858554 , Estonia, Active	Nov 27, 2019	$37K (As on Dec 31, 2022)	1 (As on Mar 31, 2022)

Apellis Pharmaceuticals got acquired by Biogen on Mar 31, 2026 at an acquisition amount of $5.6B.

Click here to take a look at Apellis Pharmaceuticals's acquisition in detail

Apellis Pharmaceuticals has raised a total funding of $213M over 13 rounds. Its first funding round was on Jul 01, 2008. Apellis Pharmaceuticals has 23 institutional investors.

Here is the list of recent funding rounds of Apellis Pharmaceuticals:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 07, 2020	2130622	Post IPO	3439434	3534488	7284695	3933769
Sep 11, 2019	7562885	Post IPO	9727747	8088323	5684954	6684211
Aug 14, 2017	9573417	Series E	1039966	1710169	Sectoral	Sofinnova Investments & 6 more

Access funding benchmarks and valuations. Sign up today!

View details of Apellis Pharmaceuticals's funding rounds and investors

The founders of Apellis Pharmaceuticals are Pascal Deschatelets and Cedric Francois. Cedric Francois is the CEO of Apellis Pharmaceuticals.

Here are the details of Apellis Pharmaceuticals' key team members:

Pascal Deschatelets: Co-Founder of Apellis Pharmaceuticals.
Contact Info: 1 email address
Cedric Francois: Co-Founder & CEO of Apellis Pharmaceuticals and founder of 2 other companies, Revon Systems and Revon Systems.
Contact Info: 1 email address

View details of Apellis Pharmaceuticals's Founder profiles and Board Members

Apellis Pharmaceuticals' employee count trend

Apellis Pharmaceuticals has 816 employees as of Mar 26. Here is Apellis Pharmaceuticals's employee count trend over the years:

Employee count trend for Apellis Pharmaceuticals

Uncover Apellis Pharmaceuticals' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Apellis Pharmaceuticals include Jazz Pharmaceuticals, Alnylam and BridgeBio. Here is the list of Top 10 competitors of Apellis Pharmaceuticals, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Prospect Venture Partners, Versant Ventures ... & 14 others	82/100
2nd	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, BB Biotech & 13 others	79/100
3rd	BridgeBio 2015, Palo Alto (United States), Acquired	Developer of therapeutics for the treatment of genetic diseases	$434M	Viking Global Investors, KKR & 20 others	79/100
4th	Alexion 1992, Zurich (Switzerland), Acquired	Developer of therapies for patients with devastating and rare diseases	$133M	Invesco, Allen & Company & 9 others	79/100
5th	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Brookside Capital & 6 others	76/100
6th	Sana Biotechnology 2018, Seattle (United States), Public	Developer of genetically engineered cell therapies for multiple disorders	$821M	Omega Funds, Bezos Expeditions & 17 others	75/100
7th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	74/100
8th	Juno Therapeutics 2013, Seattle (United States), Acquired	Global biopharmaceutical company discovering, developing, and delivering innovative medicines	$317M	Omega Funds, BB Biotech & 14 others	74/100
9th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Third Rock Ventures, Nextech Invest & 20 others	72/100
10th	Kronos Bio 2017, San Mateo (United States), Acquired	Developer of small molecule based therapeutics for cancer treatment	$271M	Omega Funds, Vida Ventures & 18 others	72/100
36th	Apellis Pharmaceuticals 2008, Crestwood (United States), Acquired	Developer of therapeutics for the treatment of rare diseases	$213M	Vivo Capital, Sectoral & 21 others	67/100